Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Fresenius Medical Care has entered into a new agreement with biotechnology giant Amgen over the anemia drug Aranesp, in order to improve care for kidney failure patients.
Subscribe to our email newsletter
Under the agreement, Fresenius Medical Care, a company focused on renal therapy, will assist Amgen in disseminating scientific information regarding the treatment of anemia to nephrologists and other dialysis experts. The new agreement runs for three years and Amgen will remain solely responsible for Aranesp.
Patients with chronic kidney disease often suffer from complications such as anemia, which occurs when failing kidneys no longer produce sufficient erythropoietin, a hormone that stimulates the production of oxygen-carrying red blood cells.
Aranesp is a novel recombinant erythropoiesis stimulating protein that stimulates erythropoiesis to produce red blood cells. Aranesp has a proven tolerability and proven efficacy, across all stages of chronic kidney disease.
“We are pleased to partner with Amgen on an expanded scale to further improve medical outcomes for dialysis patients in Europe,” said Dr Ben Lipps, CEO of Fresenius Medical Care.
“Furthermore, this agreement clearly advances our renal drug initiatives and emphasizes the position of both companies as leaders in nephrology innovation.”